Merck & Co., Inc. Stock Forecast, Price & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK stock has increased by 4.7% and is now trading at $82.95.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Tuesday, October 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Friday, July, 31st. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.14 by $0.23. The firm had revenue of $10.87 billion for the quarter, compared to analysts' expectations of $10.52 billion. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The business's revenue was down 7.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.30 EPS.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, July 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. declared that its Board of Directors has approved a share repurchase plan on Thursday, October 25th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 5.1% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 brokerages have issued 1-year price targets for Merck & Co., Inc.'s stock. Their forecasts range from $88.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.07 in the next year. This suggests a possible upside of 13.4% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

Press coverage about MRK stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck & Co., Inc. earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 10,970,000 shares, a decrease of 9.4% from the August 31st total of 12,110,000 shares. Based on an average daily volume of 7,950,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.4% of the shares of the stock are short sold.
View Merck & Co., Inc.'s Short Interest.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $82.95.

Merck & Co., Inc. has a market capitalization of $209.80 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]